EQUILLIUM, INC. Convertible Notes Payable, Noncurrent
EQUILLIUM, INC. (EQ) had Convertible Notes Payable, Noncurrent of $10.32 million as of 2018-09-30, per its 10-Q filed 2018-11-15.
Discontinued › Balance Sheet › Liabilities › Liabilities, Noncurrent › Long-Term Debt, Excluding Current Maturities › Notes Payable, Noncurrent
us-gaap:ConvertibleLongTermNotesPayable · last filed 2019-03-27
- 2018-09-30: Convertible Notes Payable, Noncurrent $10.32M.
- 2017-12-31: Convertible Notes Payable, Noncurrent $6.99M.
| Period end | Convertible Notes Payable, Noncurrent |
|---|---|
| 2018-09-30 | $10.32M 10-Q · filed 2018-11-15 |
| 2017-12-31 | $6.99M 10-K · filed 2019-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |